newsfilter
← Latest News
GlobeNewswire·

VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

VYN201 Phase 2b vitiligo trial exceeds enrollment target; Expected to be fully enrolled in December 2024 with top-line results on track for mid-2025Reported positive first-in-human Phase 1a SAD data for VYN202, with MAD